RxDoctor Payments Data

Siddharth Verma, MD

Nephrology · Parkersburg, WVNPI 1336502798

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $770 of the $1,092 with a category attached, or 70.6%. It is spread thinly across 12 manufacturers, the largest accounting for just 19.7%. Reporting peaked in 2024 at $503 and has fallen 54.8% since, to $227 in 2025.

$1,092in general payments, 2019–2025

Across 43 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$215
  • Travere Therapeutics, Inc.$198
  • Abbott$187
  • Vifor Pharma, Inc.$107
  • Bayer$105
  • Amgen$93
  • plus $186 from 6 others

What the payments were for

  • Consulting fees$15014%
  • Food & beverage$77071%
  • Education$17116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,092 in reported general payments places this provider in the 55th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$208,237
Medicare patients
519
Services billed
2,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin608$675,388
FarxigaDapagliflozin Propanediol215$205,063
KerendiaFinerenone186$180,163
FilspariSparsentan12$135,060
VeltassaPatiromer Calcium Sorbitex16$15,755
DapagliflozinDapagliflozin Propanediol16$8,361
Febuxostat41$7,562
Calcitriol396$5,945
Torsemide289$5,658
Sevelamer Carbonate31$5,542
Allopurinol436$4,597
Olmesartan Medoxomil214$4,551
Chlorthalidone269$4,226
Nifedipine ErNifedipine105$4,160
Losartan Potassium394$3,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$16$205,063215 claims
BayerKerendia$105$180,163186 claims
Travere Therapeutics, Inc.Filspari$198$135,06012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Parkersburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →